# US 2024/0390274 A1 · Method and composition for treating obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390274 A1
- Document ID: US20240390274A1
- Status: Published application
- Kind: A1
- Application number: 18/796,217
- Filed: 2024-08-06
- Published: 2024-11-28
- Earliest claimed: 2018-04-27
- Assignees: MannKind Corporation
- Applicants: MannKind Corporation
- Inventors: Michael Castagna; David Kendall; Kelly S. Kraft; Chad C. Smutney; Marshall Grant
- Web page: https://patentgrep.com/patent/US20240390274A1

## CPC

- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/28: Insulins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating obesity associated with Prader Willi Syndrome is disclosed.

## Claims

### Claim 1

A method of treating Prader-Willi syndrome in a subject, the method comprising:
administering via inhalation a dry powder composition including pramlintide and a crystalline, amorphous, or crystalline composite form a compound having a formula:

### Claim 2 (depends on 1)

The method of claim 1, wherein the administering is in a single inhalation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the administering is immediately prior to beginning a meal.

### Claim 4 (depends on 1)

The method of claim 1, wherein the administering is prandially.

### Claim 5 (depends on 4)

The method of claim 4, wherein the administering is at time 0.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is obese.

### Claim 7 (depends on 1)

The method of claim 1, wherein the dry powder composition further includes alanine, glycine, leucine, isoleucine, norleucine, serine or a combination thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the aliphatic amino acid is about 0.5% to about 30% by weight.

### Claim 9 (depends on 7)

The method of claim 7, wherein the aliphatic amino acid is L-leucine.

### Claim 10 (depends on 1)

The method of claim 1, wherein the dry powder composition further comprises insulin.

### Claim 11 (depends on 10)

The method of claim 10, wherein the insulin is a rapid acting insulin.

### Claim 12 (depends on 10)

The method of claim 10, wherein the insulin comprises up to about 30% by weight.

### Claim 13 (depends on 1)

The method of claim 1, wherein the dry powder composition further comprises a serotonin receptor agonist.

### Claim 14 (depends on 13)

The method of claim 13, wherein the serotonin receptor agonist is a triptan.

### Claim 15 (depends on 14)

The method of claim 14, wherein the triptan is sumatriptan, zolmitriptan, rizatriptan, naratriptan, almotriptan, eletriptan, or frovatriptan.

### Claim 16 (depends on 1)

The method of claim 1, wherein the dry powder composition is used in combination therapy with a rapid acting insulin, fluoxetidine, or duloxetine, or combinations thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the pramlintide is present up to 10 mg by weight.

### Claim 18 (depends on 1)

The method of claim 1, wherein the pramlintide is present up to 3 mg of dry powder composition for a single dose.

### Claim 19

A method of treating Prader-Willi syndrome, the method comprising:
providing to a subject a unit dose cartridge configured to be used in a dry powder inhaler a dry powder composition including pramlintide and a crystalline, amorphous, or crystalline composite form of a compound having a formula:

### Claim 20 (depends on 19)

The method of claim 19, wherein the dry powder inhaler is reusable.
